Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Immuno-engineered organoids for regulating the kinetics of B-cell development and antibody production

Abstract

Induction of B-cell immunity against infection depends on the initiation of the germinal center (GC) reaction in secondary lymphoid organs. Ex vivo recapitulation of the GC reaction in 2D cultures results in transient cell growth, with poor yield and short-term survival. Furthermore, no reported 2D ex vivo system can modulate the kinetics of a GC-like phenotype or the rate of antibody class switching. This protocol describes a methodology for developing immune organoids that partially mimic the B-cell zone of a lymphoid tissue, for efficient and rapid generation of B cells with a GC-like phenotype from naive murine B cells. The organoid is composed of a bioadhesive protein, gelatin, that is transformed into an ionically cross-linked hydrated network using biocompatible silicate nanoparticles (SiNPs). We explain how to establish the immune organoid culture to sustain immune cell proliferation and transformation into a GC-like phenotype. Starting with cell encapsulation in digested lymphoid tissues, clusters of proliferating B cells with a GC-like phenotype can be generated in the organoids at controlled rates, within 1 week. The culture methodology described here is currently the only one that allows the accelerated induction of a GC-like phenotype in B cells and supports a controllable immunoglobulin class-switching reaction. This method can be easily implemented in a typical tissue culture room by personnel with standard mammalian cell culture expertise.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Overview of immune organoid.
Figure 2: Organoid preparation.
Figure 3: Ex vivo induction of GC reaction within the immune organoid.
Figure 4: Whole immune organoid imaging.
Figure 5: Immune organoid flow cytometry gating strategy.

References

  1. 1

    Shi, W. et al. Transcriptional profiling of mouse B cell terminal differentiation defines a signature for antibody-secreting plasma cells. Nat. Immunol. 16, 663–673 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. 2

    Saylor, C., Dadachova, E. & Casadevall, A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 27, G38–G46 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. 3

    Sabbatino, F. et al. Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. Semin. Oncol. 41, 685–699 (2014).

    Article  CAS  Google Scholar 

  4. 4

    Weiner, L.M., Murray, J.C. & Shuptrine, C. Antibody-based immunotherapy of cancer. Cell 148, 1081–1084 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. 5

    Caspi, R. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol. 8, 970–976 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. 6

    Nutt, S.L., Hodgkin, P.D., Tarlinton, D.M. & Corcoran, L.M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160–171 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. 7

    Schiemann, B. et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293, 2111–2114 (2001).

    Article  CAS  Google Scholar 

  8. 8

    Heesters, B.A., Myers, R.C. & Carroll, M.C. Follicular dendritic cells: dynamic antigen libraries. Nat. Rev. Immunol. 14, 495–504 (2014).

    Article  CAS  Google Scholar 

  9. 9

    Cerutti, A. et al. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+ IgD+ B cell line. J. Immunol. 160, 2145–2157 (1998).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10

    von Bergwelt-Baildon, M.S. et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99, 3319–3325 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. 11

    Schultze, J.L. et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100, 2757 (1997).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. 12

    Coughlin, C.M., Vance, B.A., Grupp, S.A. & Vonderheide, R.H. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103, 2046–2054 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. 13

    Wang, X., Rodda, L.B., Bannard, O. & Cyster, J.G. Integrin-mediated interactions between B cells and follicular dendritic cells influence germinal center B cell fitness 192, 4601–4609 (2014).

  14. 14

    Allen, C.D. & Cyster, J.G. Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin. Immunol. 20, 14–25 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. 15

    Song, J. et al. Extracellular matrix of secondary lymphoid organs impacts on B-cell fate and survival. Proc. Natl. Acad. Sci. USA 110, E2915–E2924 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  16. 16

    Carrasco, Y.R. & Batista, F.D. B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1. EMBO J. 25, 889–899 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. 17

    Liu, Y.J. et al. Mechanism of antigen-driven selection in germinal centres. Nature 342, 929–931 (1989).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. 18

    Martinez-Valdez, H. et al. Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2. J. Exp. Med. 183, 971–977 (1996).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. 19

    Klein, U. & Dalla-Favera, R. Germinal centres: role in B-cell physiology and malignancy. Nat. Rev. Immunol. 8, 22–33 (2008).

    Article  CAS  Google Scholar 

  20. 20

    Nojima, T. et al. In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo. Nat. Commun. 2, 465 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. 21

    De Silva, N.S. & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137–148 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. 22

    Shulman, Z. et al. T follicular helper cell dynamics in germinal centers. Science 341, 673–677 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. 23

    Schwickert, T.A. et al. In vivo imaging of germinal centres reveals a dynamic open structure. Nature 446, 83–87 (2007).

    Article  CAS  Google Scholar 

  24. 24

    Allen, C.D. et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. 5, 943–952 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. 25

    Berek, C., Berger, A. & Apel, M. Maturation of the immune response in germinal centers. Cell 67, 1121–1129 (1991).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. 26

    Pattengale, P., Smith, R. & Gerber, P. Selective transformation of B lymphocytes by EB virus. Lancet 302, 93–94 (1973).

    Article  Google Scholar 

  27. 27

    Morello, F. et al. Differential gene expression of blood-derived cell lines in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 24, 2149–2154 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. 28

    Amoli, M., Carthy, D., Platt, H. & Ollier, W. EBV Immortalization of human B lymphocytes separated from small volumes of cryo-preserved whole blood. Int. J. Epidemiol. 37, i41–i45 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  29. 29

    Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10, 871–875 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. 30

    Glasky, M.S. & Reading, C.L. Stability of specific immunoglobulin secretion by EBV-transformed lymphoblastoid cells and human-murine heterohybridomas. Hybridoma 8, 377–389 (1989).

    Article  CAS  Google Scholar 

  31. 31

    Singh, A. & Peppas, N.A. Hydrogels and scaffolds for immunomodulation. Adv. Mat. 26, 6530–6541 (2014).

    Article  CAS  Google Scholar 

  32. 32

    Purwada, A., Roy, K. & Singh, A. Engineering vaccines and niches for immune modulation. Acta Biomater. 10, 1728–1740 (2014).

    Article  CAS  Google Scholar 

  33. 33

    Irvine, D.J., Stachowiak, A.N. & Hori, Y. Lymphoid tissue engineering: invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. Sem. Immunol. 20, 137–146 (2008).

    Article  CAS  Google Scholar 

  34. 34

    Suematsu, S. & Watanabe, T. Generation of a synthetic lymphoid tissue-like organoid in mice. Nat. Biotechnol. 22, 1539–1545 (2004).

    Article  CAS  Google Scholar 

  35. 35

    Stachowiak, A.N. & Irvine, D.J. Inverse opal hydrogel-collagen composite scaffolds as a supportive microenvironment for immune cell migration. J. Biomed. Mater. Res. A 85, 815–828 (2008).

    Article  CAS  Google Scholar 

  36. 36

    Gaharwar, A.K. et al. Shear-thinning nanocomposite hydrogels for the treatment of hemorrhage. ACS Nano 8, 9833–9842 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. 37

    Xavier, J.R. et al. Bioactive nanoengineered hydrogels for bone tissue engineering: a growth-factor-free approach. ACS Nano 9, 3109–3118 (2015).

    Article  CAS  Google Scholar 

  38. 38

    Victoratos, P. et al. FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses. Immunity 24, 65–77 (2006).

    Article  CAS  Google Scholar 

  39. 39

    Goodnow, C.C., Vinuesa, C.G., Randall, K.L., Mackay, F. & Brink, R. Control systems and decision making for antibody production. Nat. Immunol. 11, 681–688 (2010).

    Article  CAS  Google Scholar 

  40. 40

    Dumin, J.A. et al. Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen. J. Biol. Chem. 276, 29368–29374 (2001).

    Article  CAS  Google Scholar 

  41. 41

    Purwada, A. et al. Ex vivo engineered immune organoids for controlled germinal center reactions. Biomaterials 63, 24–34 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. 42

    Cerchietti, L.C. et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J. Clin. Invest. 120, 4569–4582 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. 43

    Cerchietti, L.C. et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17, 400–411 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. 44

    Ame-Thomas, P. et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26, 1053–1063 (2012).

    Article  CAS  Google Scholar 

  45. 45

    Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313–2323 (2008).

    Article  CAS  Google Scholar 

  46. 46

    Cayrol, F. et al. Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood 125, 841–851 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. 47

    Kasturi, S.P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543–547 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. 48

    Chiarle, R. et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat. Med. 14, 676–680 (2008).

    Article  CAS  Google Scholar 

  49. 49

    Davis, R.E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88–92 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. 50

    Hailfinger, S. et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. USA 106, 19946–19951 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51

    Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676–1679 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. 52

    Lenz, G. et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J. Exp. Med. 204, 633–643 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. 53

    Lenz, G. et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. USA 105, 13520–13525 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  54. 54

    Nagel, D. et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 22, 825–837 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. 55

    Tian, Y.F. et al. Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials 73, 110–119 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. 56

    Caganova, M. et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J. Clin. Invest. 123, 5009–5022 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. 57

    Béguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677–692 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. 58

    Su, I.H. et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4, 124–131 (2003).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. 59

    Fontan, L. et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 22, 812–824 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. 60

    Clozel, T. et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B cell lymphoma. Cancer Discov. 3, 1002–1019 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. 61

    Linterman, M.A. How T follicular helper cells and the germinal centre response change with age. Immunol. Cell Biol. 92, 72–79 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. 62

    Purwada, A. et al. Self-assembly protein nanogels for safer cancer immunotherapy. Adv. Healthc. Mater. 5, 1413–1419 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. 63

    Singh, A. et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J. Control. Release 155, 184–192 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. 64

    Singh, A., Suri, S. & Roy, K. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 30, 5187–5200 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. 65

    Singh, A. et al. Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. Mol. Ther. 16, 2011–2021 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. 66

    Moon, J.J. et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl. Acad. Sci. USA 109, 1080–1085 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  67. 67

    Look, M. et al. Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J. Clin. Invest. 123, 1741–1749 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. 68

    Zhou, P. et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 506, 52–57 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. 69

    Qin, H. et al. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity. Blood 114, 4142–4149 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. 70

    Chiarle, R. et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11, 623–629 (2005).

    Article  CAS  Google Scholar 

  71. 71

    Chiarle, R. et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101, 1919–1927 (2003).

    Article  CAS  Google Scholar 

  72. 72

    Krzyzak, L. et al. CD83 modulates B cell activation and germinal center responses. J. Immunol. 196, 3581–3594 (2016).

    Article  CAS  Google Scholar 

  73. 73

    Klein, U. et al. Transcriptional analysis of the B cell germinal center reaction. Proc. Natl. Acad. Sci. USA 100, 2639–2644 (2003).

    Article  CAS  Google Scholar 

  74. 74

    Ortega-Molina, A. et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat. Med. 21, 1199–1208 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. 75

    Gorbet, M.B. & Sefton, M.V. Endotoxin: the uninvited guest. Biomaterials 26, 6811–6817 (2005).

    Article  CAS  Google Scholar 

  76. 76

    Round, J.L. et al. Scaffold protein Dlgh1 coordinates alternative p38 kinase activation, directing T cell receptor signals toward NFAT but not NF-kappaB transcription factors. Nat. Immunol. 8, 154–161 (2007).

    Article  CAS  Google Scholar 

  77. 77

    Watarai, H., Nakagawa, R., Omori-Miyake, M., Dashtsoodol, N. & Taniguchi, M. Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat. Protoc. 3, 70–78 (2008).

    Article  CAS  Google Scholar 

  78. 78

    Moutai, T., Yamana, H., Nojima, T. & Kitamura, D. A novel and effective cancer immunotherapy mouse model using antigen-specific B Cells selected in vitro. PloS One 9, e92732 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. 79

    Vuong, B.Q. et al. Specific recruitment of protein kinase A to the immunoglobulin locus regulates class-switch recombination. Nat. Immunol. 10, 420–426 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. 80

    Shinkura, R. et al. Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat. Immunol. 5, 707–712 (2004).

    Article  CAS  Google Scholar 

  81. 81

    Liu, N., Ohnishi, N., Ni, L., Akira, S. & Bacon, K.B. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat. Immunol. 4, 687–693 (2003).

    Article  CAS  Google Scholar 

  82. 82

    Talay, O. et al. IgE(+) memory B cells and plasma cells generated through a germinal-center pathway. Nat. Immunol. 13, 396–404 (2012).

    Article  CAS  Google Scholar 

  83. 83

    Fischer, A.H., Jacobson, K.A., Rose, J. & Zeller, R. Cutting sections of paraffin-embedded tissues. CSH Protoc. 2008 http://dx.doi.org/10.1101/pdb.prot4987 (2008).

  84. 84

    Lee, T.T. et al. Light-triggered in vivo activation of adhesive peptides regulates cell adhesion, inflammation and vascularization of biomaterials. Nat. Mater. 14, 352–360 (2015).

    Article  CAS  Google Scholar 

  85. 85

    Whitmire, R.E. et al. Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins. Biomaterials 33, 7665–7675 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. 86

    Syrbu, S.I. & Cohen, M.B. An enhanced antigen-retrieval protocol for immunohistochemical staining of formalin-fixed, paraffin-embedded tissues. Methods Mol. Biol. 717, 101–110 (2011).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge financial support from a National Science Foundation (NSF) CAREER Award (DMR-1554275 (to A.S.)) and the National Institutes of Health (1R21CA185236-01, to A.S.). We thank D. Kitamura at Tokyo University of Science for providing 40LB cells. We thank L. Cerchietti and his laboratory at Weill Cornell Medical College of Cornell University for providing histology imaging expertise and A. Gaharwar and his laboratory at Texas A&M University for silicate nanoparticle imaging expertise. All procedures were approved by Cornell University's Institutional Animal Care and Use Committee. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Author information

Affiliations

Authors

Contributions

A.P. and A.S. wrote the manuscript. A.P. conducted the experiments, and A.P. and A.S. performed data analysis.

Corresponding author

Correspondence to Ankur Singh.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Integrated supplementary information

Supplementary Figure 1 Ex vivo induction into CD83 phenotype within the immune organoid.

Naïve B cells with 40LB cells were co-encapsulated with the immune organoids. Left panel shows the histogram overlay of flow cytometry analysis indicating a shift in CD84 signal. Right panel indicates Median fluorescence intensity of CD19+CD83+ cells inside the organoids and comparative controls (*p<0.05, Analysis of variance (ANOVA), n=3, data represents Mean ± Standard Error)

Supplementary information

Supplementary Text and Figures

Supplementary Figure 1. (PDF 133 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Purwada, A., Singh, A. Immuno-engineered organoids for regulating the kinetics of B-cell development and antibody production. Nat Protoc 12, 168–182 (2017). https://doi.org/10.1038/nprot.2016.157

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links